Epzicom Approval History
- FDA approved: Yes (First approved August 2nd, 2004)
- Brand name: Epzicom
- Generic name: abacavir and lamivudine
- Company: GlaxoSmithKline
- Treatment for: HIV Infection
Epzicom (abacavir and lamivudine) is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for use with other antiretroviral drugs for the treatment of HIV-1 infection in adults.
Development History and FDA Approval Process for Epzicom
|Aug 2, 2004||Epzicom GlaxoSmithKline - Treatment for HIV Infection|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.